GlassScriptPhysician profile
Suresh A Patel
NPI 1912938176
$10,232.30
in general payments reported to CMS, 2019-2025
53 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $938 · 2021: $1,519 · 2022: $1,684 · 2023: $1,363 · 2024: $1,863 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,914.82 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,680.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,366.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $934.88 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $629.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $572.79 | 2019-2024 | Belsomra, Verquvo, Steglatro |
| Pfizer INC. | $529.61 | 2019-2025 | |
| Astellas Pharma US INC | $430.74 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $352.41 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $292.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.74 | 2019-2025 | Tradjenta, Jardiance |
| Amgen INC. | $231.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Esperion Therapeutics, INC. | $214.17 | 2020-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $202.92 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $200.67 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $168.18 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.